Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.
Parisi M, Dogliotti I, Clerico M, Bertuzzo D, Benevolo G, Orsucci L, Schiavetti I, Cavallo R, Cavallo F, Ragaini S, Di Liberto A, Ferrante M, Bondielli G, Artusi CA, Drandi D, Lopiano L, Ferrero B, Ferrero S. Parisi M, et al. Among authors: bertuzzo d. Eur J Neurol. 2022 Dec;29(12):3611-3622. doi: 10.1111/ene.15553. Epub 2022 Sep 25. Eur J Neurol. 2022. PMID: 36083713 Free PMC article.
Droplet Digital PCR Assay for MYD88 L265P : Clinical Applications in Waldenström Macroglobulinemia.
Lo Schirico M, Ferrante M, Dogliotti I, Zamò A, Ferrero B, Bertuzzo D, Benevolo G, Omedè P, Cavallo F, Ladetto M, Boccadoro M, Drandi D, Ferrero S. Lo Schirico M, et al. Among authors: bertuzzo d. Hemasphere. 2020 Jan 3;4(1):e324. doi: 10.1097/HS9.0000000000000324. eCollection 2020 Feb. Hemasphere. 2020. PMID: 32072140 Free PMC article. No abstract available.
Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report.
Agostini A, Merli M, Avallone G, Burzi L, Mastorino L, Parisi M, Bertuzzo D, Ferrero B, Cerrato M, Badellino S, Molinaro L, Lopiano L, Ribero S, Quaglino P. Agostini A, et al. Among authors: bertuzzo d. Acta Derm Venereol. 2021 May 10;101(5):adv00452. doi: 10.2340/00015555-3798. Acta Derm Venereol. 2021. PMID: 33846760 Free PMC article. No abstract available.
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; Italian Migraine Registry study group. Barbanti P, et al. Among authors: bertuzzo d. J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3. J Neurol. 2024. PMID: 38564057 Free PMC article. No abstract available.
Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis.
Pagani M, Chiò A, Valentini MC, Öberg J, Nobili F, Calvo A, Moglia C, Bertuzzo D, Morbelli S, De Carli F, Fania P, Cistaro A. Pagani M, et al. Among authors: bertuzzo d. Neurology. 2014 Sep 16;83(12):1067-74. doi: 10.1212/WNL.0000000000000792. Epub 2014 Aug 13. Neurology. 2014. PMID: 25122207 Free article.
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study.
Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Lovati C, Bertuzzo D, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Schiano Di Cola F, Ranieri A, Colombo B, Bono F, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group. Vernieri F, et al. Among authors: bertuzzo d. Eur J Neurol. 2022 Apr;29(4):1198-1208. doi: 10.1111/ene.15197. Epub 2021 Dec 6. Eur J Neurol. 2022. PMID: 34826192
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience.
Altamura C, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Schiano Di Cola F, d'Onofrio F, Finocchi C, Bertuzzo D, Bono F, Ranieri A, Albanese M, Messina R, Doretti A, Di Piero V, Cevoli S, Barbanti P, Vernieri F; GARLIT Study Group. Altamura C, et al. Among authors: bertuzzo d. J Neurol. 2022 Nov;269(11):5848-5857. doi: 10.1007/s00415-022-11226-4. Epub 2022 Jun 28. J Neurol. 2022. PMID: 35763113 Free PMC article.
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study.
Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Rao R, d'Onofrio L, Finocchi C, Aguggia M, Bono F, Ranieri A, Albanese M, Di Piero V, Cevoli S, Altamura C, Barbanti P; GARLIT Study Group. Vernieri F, et al. Eur J Neurol. 2023 Jan;30(1):224-234. doi: 10.1111/ene.15563. Epub 2022 Sep 26. Eur J Neurol. 2023. PMID: 36097739 Free PMC article.
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; ERT; for the Italian Migraine Registry study group. Barbanti P, et al. Among authors: bertuzzo d. J Neurol. 2024 May;271(5):2434-2443. doi: 10.1007/s00415-023-12103-4. Epub 2024 Jan 17. J Neurol. 2024. PMID: 38231271 Free PMC article.
33 results